Details for New Drug Application (NDA): 022030

✉ Email this page to a colleague

NDA 022030 describes TOVIAZ, which is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TOVIAZ profile page.

The generic ingredient in TOVIAZ is fesoterodine fumarate. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fesoterodine fumarate profile page.

Summary for 022030

Tradename:	TOVIAZ
Applicant:	Pfizer
Ingredient:	fesoterodine fumarate
Patents:	3

Suppliers and Packaging for NDA: 022030

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0242	0069-0242-30	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0242-30)
TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0244	0069-0244-30	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0244-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	4MG
Approval Date:	Oct 31, 2008	TE:	AB	RLD:	Yes
Patent:	7,807,715*PED	Patent Expiration:	Dec 7, 2027	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	8,088,398*PED	Patent Expiration:	Dec 7, 2027	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	8,501,723*PED	Patent Expiration:	Dec 7, 2027	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 022030

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	8,338,478	⤷ Start Trial
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	7,384,980	⤷ Start Trial
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	7,384,980	⤷ Start Trial
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	7,985,772	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.